Spotlight On... Transplant Genomics, Mayo Clinic join forces on enabling personalized immunosuppression for transplant patients; Greatbatch rebrands itself; Atlantic Diagnostic Labs launches liquid biopsy for colon cancer precursor; and more...

Transplant Genomics and the Mayo Clinic are teaming up to develop, validate and commercialize diagnostic tests with the goal of personalizing immunosuppression for solid organ transplant patients. The collaboration will include the assessment Transplant Genomics' TruGraf test for renal transplant monitoring and the co-development of tests and technologies for other targets, including heart and liver transplantation. Release

> Greatbatch ($GB) will rename itself Integer Holdings and trade under the symbol ITGR effective July 1. Release

> Atlantic Diagnostic Laboratories launched PolypDx, a noninvasive, urine-based diagnostic for the detection of adenomatous polyps, the precursor to colon cancer. Release

> Masimo ($MASI) obtained 510(k) clearance for Radius-7, the first and only wearable, tetherless noninvasive rainbow monitor. Release

Suggested Articles

The FDA will be working with government and public-private partners to distribute and evaluate 3D designs and models.

The FDA issued a wide-ranging emergency policy allowing alternative devices to be used as potentially lifesaving ventilators amid new shortages.

Hospitals in the New York City area are turning to a private distributor to airlift millions of protective masks out of China.